Acurx Pharmaceuticals, Inc. Reports Second Quarter 2023 Results and Provides Business Update Aug 14, 2023
Acurx Pharmaceuticals to Discuss Second Quarter 2023 Financial Results and Provide Business Update Jul 24, 2023
Acurx Pharmaceuticals to Participate in the Maxim Group LLC Virtual Healthcare Conference on Tuesday, June 20, 2023 to Thursday, June 22, 2023 at 9 am ET Jun 15, 2023
Acurx Pharmaceuticals, Inc. Announces Pricing of $4.0 Million Registered Direct Offering May 16, 2023
Acurx Pharmaceuticals, Inc. Reports First Quarter 2023 Results and Provides Business Update May 12, 2023
Acurx Pharmaceuticals to Discuss First Quarter 2023 Financial Results and Provide Business Update May 5, 2023
Acurx Announces Ibezapolstat Scientific Poster and Update on its Pol IIIC Pipeline Presented at ECCMID 2023 Scientific Conference Apr 19, 2023
FDA Accepts Interim Analysis Plan for Ongoing Phase 2b Ibezapolstat Clinical Trial and Acurx Announces Presentations at ECCMID 2023 Scientific Conference Apr 11, 2023
Acurx Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2022 Results and Provides Business Update Mar 16, 2023
